Bio Path Company Top Insiders
BPTH Stock | USD 0.82 0.01 1.23% |
Under 75 percent of all Bio Path's insiders are aggressively buying. The analysis of the overall insider sentiment regarding Bio Path Holdings suggests that a large number of insiders are very bullish. Bio Path employs about 10 people. The company is managed by 10 executives with a total tenure of roughly 11 years, averaging almost 1.0 years of service per executive, having 1.0 employees per reported executive.
Douglas Morris Director Co-Founder and Director |
Bio Path's Insider Buying Vs Selling
75
Selling | Buying |
Latest Trades
2019-01-18 | Armistice Capital Master Fund | Disposed 64457 @ 2.66 | View | ||
2015-07-13 | Michael J Garrison | Acquired 7343 @ 1.22 | View | ||
2015-07-09 | Michael J Garrison | Acquired 8724 @ 1.17 | View | ||
2015-07-08 | Michael J Garrison | Acquired 60000 @ 1.19 | View |
Monitoring Bio Path's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Bio |
Bio Path Management Team Effectiveness
The company has return on total asset (ROA) of (1.4003) % which means that it has lost $1.4003 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.6618) %, meaning that it created substantial loss on money invested by shareholders. Bio Path's management efficiency ratios could be used to measure how well Bio Path manages its routine affairs as well as how well it operates its assets and liabilities. The Bio Path's current Return On Tangible Assets is estimated to increase to -5.46. The Bio Path's current Return On Capital Employed is estimated to increase to -13.17. As of now, Bio Path's Net Tangible Assets are increasing as compared to previous years.The current Common Stock Shares Outstanding is estimated to decrease to about 292.6 K. The current Net Loss is estimated to decrease to about (9.9 M)
Bio Path Workforce Comparison
Bio Path Holdings is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 709. Bio Path claims roughly 10.0 in number of employees contributing just under 2% to equities under Health Care industry.
Bio Path Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bio Path insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bio Path's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Bio Path insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cleaver Heath over a month ago Acquisition by Cleaver Heath of 10000 shares of Bio Path subject to Rule 16b-3 | ||
Garrison Michael J. over a month ago Disposition of 25000 shares by Garrison Michael J. of Bio Path at 0. subject to Rule 16b-3 | ||
Garrison Thomas E over two months ago Acquisition by Garrison Thomas E of 400000 shares of Bio Path at 1.5 subject to Rule 16b-3 | ||
Cleaver Heath over two months ago Acquisition by Cleaver Heath of 2000 shares of Bio Path at 1.55 subject to Rule 16b-3 | ||
Sherwood Aline over three months ago Acquisition by Sherwood Aline of 2000 shares of Bio Path at 1.55 subject to Rule 16b-3 | ||
Aubert Paul over three months ago Acquisition by Aubert Paul of 10000 shares of Bio Path subject to Rule 16b-3 | ||
Sherwood Aline over three months ago Acquisition by Sherwood Aline of 2000 shares of Bio Path at 1.55 subject to Rule 16b-3 | ||
Nielsen Peter Henry over three months ago Acquisition by Nielsen Peter Henry of 25000 shares of Bio Path at 1.55 subject to Rule 16b-3 |
Bio Path Notable Stakeholders
A Bio Path stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Bio Path often face trade-offs trying to please all of them. Bio Path's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Bio Path's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Douglas Morris | Co-Founder and Director | Profile | |
Michael MBA | VP Operations | Profile | |
Alan MacKenzie | Consultant | Profile | |
Thomas Walker | Consultant | Profile | |
MBA Ashizawa | Development Research | Profile | |
Peter MBA | Chairman, CoFounder | Profile | |
Jeffery MD | Consultant | Profile | |
Victoria Rac | Regulatory Consultant | Profile | |
Anthony Price | Accounting Finance | Profile | |
MBA MBA | Development Research | Profile |
About Bio Path Management Performance
The success or failure of an entity such as Bio Path Holdings often depends on how effective the management is. Bio Path management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Bio management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Bio management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (5.74) | (5.46) | |
Return On Capital Employed | (13.87) | (13.17) | |
Return On Assets | (5.74) | (5.46) | |
Return On Equity | (41.93) | (39.83) |
Bio Path Workforce Analysis
Traditionally, organizations such as Bio Path use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Bio Path within its industry.Bio Path Manpower Efficiency
Return on Bio Path Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 1.6M | |
Net Loss Per Executive | 1.6M | |
Working Capital Per Employee | 113.6K | |
Working Capital Per Executive | 113.6K |
Complementary Tools for Bio Stock analysis
When running Bio Path's price analysis, check to measure Bio Path's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Path is operating at the current time. Most of Bio Path's value examination focuses on studying past and present price action to predict the probability of Bio Path's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Path's price. Additionally, you may evaluate how the addition of Bio Path to your portfolios can decrease your overall portfolio volatility.
Fundamental Analysis View fundamental data based on most recent published financial statements | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Money Managers Screen money managers from public funds and ETFs managed around the world |